CSR News_ESG_Fosun Pharma

We are committed to sustainable growth in both talent and products,
and contribute to the health and well-being of humanity through continuous innovation and equitable healthcare access.

2025-07-26

Fosun Pharma Achieves AA Rating in MSCI ESG Assessment

More
2025-05-09

Fosun Pharma Joins Pharmaceutical Supply Chain Initiative (PSCI), Collaborating with Global Partners to Build Sustainable Supply Chains

More
2025-04-07

Fosun Pharma Announces 2024 ESG and Sustainability Report: Continuous Innovation for the Sustainable Development of Inclusive Healthcare

More
2024-03-27

Fosun Pharma Releases Its First ESG and Sustainability Report Deepening ESG Practice and Driving Sustainable Development Through Innovation

More
2023-09-25

Caring for Women: Shanghai-Yunnan Cooperation to Enhance Primary Healthcare Standards Fosun Pharma and the Shanghai Soong Ching Ling Foundation Launch the Pink & Blue Ribbon Public Welfare Campaign for Cervical and Breast Cancer Screening at Xishuangbanna

More
2023-04-26

Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative

More
2023-03-29

Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public

More
2022-10-14

Fosun Pharma’s MSCI ESG Rating Upgraded to A

More
2020-12-23

STARBUDS program initiated to provide life-cycle care for children with rare diseases

More

Total ：112 Home Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last The Number Of Pages ：1/13 GO

上海尊龙凯时医药集团

尊龙凯时 - 人生就是搏!尊龙凯时

Our Company

Our Business

R&D

ESG

Investor Relations

News

Careers

Fosun Pharma Achieves AA Rating in MSCI ESG Assessment

Fosun Pharma Joins Pharmaceutical Supply Chain Initiative (PSCI), Collaborating with Global Partners to Build Sustainable Supply Chains

Fosun Pharma Announces 2024 ESG and Sustainability Report: Continuous Innovation for the Sustainable Development of Inclusive Healthcare

Fosun Pharma Releases Its First ESG and Sustainability Report Deepening ESG Practice and Driving Sustainable Development Through Innovation

Caring for Women: Shanghai-Yunnan Cooperation to Enhance Primary Healthcare Standards Fosun Pharma and the Shanghai Soong Ching Ling Foundation Launch the Pink & Blue Ribbon Public Welfare Campaign for Cervical and Breast Cancer Screening at Xishuangbanna

Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative

Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public

Fosun Pharma’s MSCI ESG Rating Upgraded to A

STARBUDS program initiated to provide life-cycle care for children with rare diseases